• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Gilead’s Kite Expands Arcellx Pact with $285M Equity Investment, Upfront Cash

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 15, 2023 at 11:12: AM
via Gilead subsidiary Kite on Wednesday broadened the scope of its existing collaboration with Arcellx. The two companies will now also evaluate the investigational cell therapy CART-ddBCMA, originally being developed for multiple myeloma, as a treatment for lymphomas.

article source
 

<



Similar threads

cafead
Gilead&#039;s Kite exits China cell therapy joint venture with Fosun Pharma
Replies
0
Views
8
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Gilead’s Kite Gets FDA Approval for Faster CAR T Therapy Manufacturing
Replies
0
Views
288
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Gilead cuts 7% of staff at Kite Pharma unit as &#039;refreshed business strategy&#039;...
Replies
0
Views
90
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Gilead picks former Roche executive to run cell therapy unit Kite
Replies
0
Views
258
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Gilead lands new cell therapy for Kite in $225M Arcellx deal
Replies
0
Views
220
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote